Low-Dose Ketamine for Bipolar Depression: Efficacy and Safety Data

Low dose ketamine depression treatment may reduce bipolar depressive symptoms quickly in some adults, but the evidence is still limited and it is not an FDA-approved treatment for bipolar depression. Small clinical trials of intravenous ketamine found antidepressant effects within hours, usually while participants continued lithium or valproate. The short duration of benefit, limited long-term data, and potential for dissociation, blood pressure increases, and mood changes mean treatment decisions need careful psychiatric assessment and monitoring.

Bipolar disorder involves episodes of depression and episodes of mania or hypomania. The National Institute of Mental Health notes that depressive episodes can be a major part of bipolar disorder and can substantially affect daily functioning. For people whose bipolar depression has not improved with standard care, ketamine is being studied as a rapid-acting option, not a replacement for a complete treatment plan.

What the clinical studies found

The best-known randomized trials evaluated racemic ketamine, which contains two mirror-image forms of ketamine, given intravenously at 0.5 mg/kg over 40 minutes. Participants had treatment-resistant bipolar depression and remained on lithium or valproate.

In a small double-blind crossover trial by Diazgranados and colleagues, 71% of participants met the study's response threshold 24 hours after ketamine, compared with 6% after saline placebo. The response threshold was at least a 50% reduction on the Montgomery-Asberg Depression Rating Scale, a clinician-rated depression measure. The study was small, so the result is encouraging rather than definitive. Read the original Diazgranados et al. randomized trial for its design and limitations.

A later National Institute of Mental Health crossover study also reported rapid improvement after a single infusion, while showing that benefit often diminished over the following days. This is the central practical limitation: a fast response does not establish a durable treatment effect.

According to Diazgranados et al., 71% of participants met the trial's depression-response threshold 24 hours after ketamine, versus 6% after placebo. That statistic describes one small, highly selected study population. It should not be read as a prediction of how any individual will respond in routine care.

Why ketamine may act quickly

Ketamine is an N-methyl-D-aspartate, or NMDA, receptor antagonist. NMDA receptors are part of the brain's glutamate signaling system. Researchers think ketamine may trigger downstream changes in glutamate signaling and synaptic plasticity, which is the brain's ability to alter connections between nerve cells.

This mechanism differs from conventional antidepressants that primarily act through monoamine signaling. It helps explain why ketamine can have a rapid effect, but it does not prove which people with bipolar depression will benefit or how to maintain benefit safely. For a deeper explanation of the proposed biology, see our guide to ketamine and neuroplasticity mechanisms.

Safety questions specific to bipolar depression

The key concern is an affective switch, meaning new or worsening mania or hypomania during or after treatment. In the small controlled trials, reported switches were uncommon. However, those studies generally required participants to continue a therapeutic mood stabilizer, so they cannot establish that ketamine is equally safe without one.

A 2021 systematic review of ketamine for bipolar depression concluded that the available studies showed promising short-term outcomes but highlighted their small samples, short follow-up, and need for stronger safety data. See the systematic review indexed by PubMed for the underlying evidence.

Dissociation is another relevant effect. A person may feel detached from their body or surroundings, have altered perception, or feel confused for a short period. These effects in infusion studies generally resolved during the observation period, but they are still a reason for supervised administration and for avoiding driving or other safety-sensitive activities afterward.

Ketamine can also temporarily raise blood pressure and heart rate. That may require added review for people with cardiovascular conditions or medicines that affect blood pressure. Learn what clinicians commonly monitor in our overview of cardiovascular monitoring with ketamine.

How ketamine compares with established treatment

Ketamine's main potential advantage is speed. Standard bipolar depression medicines may take days or weeks to show a full benefit, and some require gradual dose increases. Ketamine studies observed changes within hours, but the benefit from one infusion often faded within days to one or two weeks.

That makes ketamine a possible adjunct or bridge in carefully selected cases, not a simple substitute for maintenance treatment. Direct comparisons with lamotrigine, quetiapine, lithium, or other established approaches are difficult because study populations, endpoints, and follow-up periods differ. A larger effect in a short ketamine study does not show better long-term outcomes.

Intranasal esketamine, sold in the United States as Spravato, is a form of ketamine approved by the FDA for certain adults with treatment-resistant major depressive disorder and for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior. Its approved labeling does not include bipolar depression. The FDA prescribing information for Spravato explains its approved uses and safety requirements.

What treatment discussions should cover

A useful evaluation starts with the diagnosis and current mood state. Bipolar depression, mixed symptoms, psychosis, substance use, medication interactions, and a past history of mania can all affect whether ketamine is appropriate and how treatment should be monitored.

Who may need extra caution

People with active mania, psychosis, uncontrolled hypertension, significant cardiovascular concerns, or a substance use history may need additional assessment before ketamine is considered. These factors do not automatically determine eligibility, but they can change the balance of potential benefit and risk.

Medication review matters as well. Sedatives, alcohol, benzodiazepines, and other medicines can affect safety, alertness, or treatment response. See our ketamine drug-interactions guide and our review of ketamine and alcohol safety risks for discussion points to raise with a prescriber.

What remains unknown

The most important unanswered questions are how long benefits last, which repeat-dose schedules are effective, whether maintenance treatment is safe over longer periods, and which patients are most likely to respond without destabilization. Biomarker research is exploring whether brain imaging, blood markers, or electrical brain activity might help predict response, but these tools are not established for routine selection. Read about the current research in our ketamine response biomarkers article.